LIPTRUZET Drug Patent Profile

Which patents cover Liptruzet, and what generic alternatives are available?

Liptruzet is a drug marketed by Organon and is included in one NDA.

The generic ingredient in LIPTRUZET is atorvastatin calcium; ezetimibe. There are sixty-two drug master file entries for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.

Summary for LIPTRUZET

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LIPTRUZET

US Patents and Regulatory Information for LIPTRUZET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	LIPTRUZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	200153-001	May 3, 2013		DISCN	Yes	No
Organon	LIPTRUZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	200153-004	May 3, 2013		DISCN	Yes	No
Organon	LIPTRUZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	200153-002	May 3, 2013		DISCN	Yes	No
Organon	LIPTRUZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	200153-003	May 3, 2013		DISCN	Yes	No

International Patents for LIPTRUZET

See the table below for patents covering LIPTRUZET around the world.

Country	Patent Number	Title	Estimated Expiration
Uruguay	24985	FORMAS CRISTALINAS HIDRATADAS DE ATORVASTATINA FORMA I
Netherlands	300172
Poland	324496
Austria	180249
Norway	980207
Netherlands	300132

Supplementary Protection Certificates for LIPTRUZET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	SZ 26/2005	Austria
0720599	C300688	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NAT. REGISTRATION NO/DATE: RVG114002-004RVG 114008-010 2014110811; FIRST REGISTRATION: 13-9663 - 9665 20140724
0720599	92545	Luxembourg		PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
0720599	300688	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NATIONAL REGISTRATION NO/DATE: RVG114002-004 20140811; FIRST REGISTRATION: NO 13-9663 - 9665 20140724
0720599	SZ 20/2003	Austria		PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON
0247633	62/1997	Austria		PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107

LIPTRUZET Investment Scenario and Fundamentals Analysis

Last updated: February 21, 2026

What is LIPTRUZET?

LIPTRUZET, marketed by Novartis, is a combination drug indicated for lowering LDL cholesterol levels. It combines:

• Ezetimibe (10 mg) – a cholesterol absorption inhibitor
• Rosuvastatin (10 mg or 20 mg) – a statin class lipid-lowering agent

Approved by the FDA in August 2016, LIPTRUZET targets patients intolerant to high-dose statins or those needing additional LDL reduction despite statin therapy alone.

Market Overview and Growth Drivers

Size and Growth

The global lipid-lowering agents market was valued at USD 20.7 billion in 2022. It is projected to reach USD 27.3 billion by 2028 with a CAGR of 4.7% (Fortune Business Insights, 2023).

Key Drivers

• Rising prevalence of hypercholesterolemia and cardiovascular diseases globally
• Increased awareness of cardiovascular risk factors
• Growing use of combination therapies to achieve LDL targets
• Patent expiry of major statins expanding market opportunities for combination drugs

Competitive Landscape

Major competitors include:

• Lipitor (atorvastatin)
• Crestor (rosuvastatin) monotherapy
• Ezetimibe alone (Zetia)
• PCSK9 inhibitors (evolocumab, alirocumab)

Market share is divided among these classes, but combination drugs like LIPTRUZET offer benefits in adherence and efficacy, especially in complex patient profiles.

Regulatory and Patent Status

• FDA approval: August 2016, indication for adult patients with primary hyperlipidemia or mixed dyslipidemia
• Patent status: Patents expire in the U.S. around 2028-2030. Generic versions of ezetimibe and rosuvastatin have entered the market, pressuring branded sales.
• Additional approvals: LIPTRUZET has not yet secured significant regulatory extensions or new indications.

Revenue and Commercial Potential

Sales Performance

• Novartis reported LIPTRUZET sales of approximately USD 150 million in 2022.
• Growth is limited by generic competition and patent cliffs.

Market Penetration Strategies

• Positioning as a convenient, synergistic therapy
• Targeting patients with moderate to severe hyperlipidemia
• Collaborations with healthcare providers to improve prescribing patterns

Revenue Risks

• Expiration of key patents within the next 3-5 years
• Increasing generic competition reducing margins
• Slow adoption in some regions due to pricing and reimbursement challenges

Investment Fundamentals

Strengths

• Proven efficacy combining two established drugs
• Established market demand for combination lipid-lowering therapies
• Strong brand recognition from Novartis

Weaknesses

• Patent expiry approaching
• Competitors offering generic alternatives
• Limited pipeline potential for LIPTRUZET itself

Opportunities

• Expansion into new territories
• Potential for new indications or formulations
• Developing combination products with PCSK9 inhibitors

Threats

• Price erosion due to generics
• Regulatory hurdles for alternative combination formulations
• Competition from novel lipid-lowering agents with better efficacy or safety profiles

Financial Outlook

• Revenue growth is likely to plateau post-patent expiration unless new indications or formulations are introduced
• R&D investments necessary to maintain market share or develop next-generation products

Conclusion

LIPTRUZET presents limited near-term growth prospects. Its market value relies on patent exclusivity, regulatory positioning, and competitive landscape. Long-term viability depends on Novartis’s capacity to innovate or expand indications. Investors should monitor patent statuses, market share shifts, and emerging technological alternatives.

Key Takeaways

• The global hyperlipidemia market remains robust with steady growth driven by rising cardiovascular disease prevalence.
• LIPTRUZET’s sales are constrained by patent expiry timelines and increasing generic competition.
• The drug’s value proposition hinges on its combination efficacy but faces challenges from novel therapies.
• Future investment relies on potential pipeline developments, geographic expansion, and strategic partnerships.
• Near-term risks primarily stem from pricing pressures and regulatory changes affecting branded drug sales.

FAQs

1. When do the patents on LIPTRUZET expire?
Patents in the US are expected to expire between 2028 and 2030, enabling generic competition.

2. What are the main competitors for LIPTRUZET?
Generic ezetimibe and rosuvastatin, as well as branded monotherapies like Lipitor and Crestor, and PCSK9 inhibitors.

3. Are there any approved new indications for LIPTRUZET?
No. Its approved indication remains for primary hyperlipidemia in adults.

4. What are the growth prospects for LIPTRUZET in emerging markets?
Potential exists due to increasing cardiovascular disease burden; however, market penetration depends on pricing, reimbursement, and regulatory pathways.

5. How does LIPTRUZET compare to monotherapy options?
It offers superior LDL reduction for patients needing combination therapy but faces market challenges due to generic pricing pressures.

---

References

1. Fortune Business Insights. (2023). Lipid-lowering Agents Market Size, Share & Industry Analysis. Retrieved from [URL]
2. Novartis Annual Report. (2022).
3. U.S. Food and Drug Administration. (2016). FDA Drug Approvals and Labeling.
4. MarketWatch. (2023). Lipid-Lowering Drugs Market Trends.
5. Reuters. (2022). Patent expirations impact on pharmaceutical sales.